中国肺癌杂志最新文献

{"title":"[Advances in Radiomics for Immune Checkpoint Inhibitor-related Pneumonitis \u2029of Lung Cancer].","authors":"Dong Zhang, Li Peng, Tianming Zhang, Fanqi Wu, Hong Wang","doi":"10.3779/j.issn.1009-3419.2026.101.17","DOIUrl":"10.3779/j.issn.1009-3419.2026.101.17","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) have significantly improved the prognosis of patients with lung cancer. However, checkpoint inhibitor-related pneumonitis (CIP), as one of the most severe immune-related adverse events, lacks well-defined diagnostic criteria and reliable risk stratification tools. Radiomics enables high-throughput feature extraction from computed tomography images and provides a non-invasive technical approach for the early identification and risk stratification of CIP. This article systematically reviews the recent advances in the application of radiomics to risk prediction, diagnosis and differential diagnosis, and prognostic evaluation of CIP in lung cancer immunotherapy. Furthermore, it explores the value of integrating radiomics with multi-omics data in elucidating the pathogenesis of CIP, as well as the role of explainable artificial intelligence (XAI) in enhancing the clinical trustworthiness of models.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 7","pages":"540-547"},"PeriodicalIF":0.0,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expert Consensus on Immunotherapy for Extensive-stage Small Cell Lung Cancer \u2029Based on Molecular Subtyping].","authors":"","doi":"10.3779/j.issn.1009-3419.2026.102.18","DOIUrl":"10.3779/j.issn.1009-3419.2026.102.18","url":null,"abstract":"<p><p>Immune checkpoint inhibitors combined with Platinum-based Etopositde chemotherapy have become the first-line standard treatment for extensive-stage small cell lung cancer (ES-SCLC). However, treatment benefit varies substantially among patients, and the proportion of long-term survivors remains limited. In recent years, the molecular classification framework comprising SCLC-A, SCLC-N, SCLC-P and SCLC-I, based on the expression patterns of ASCL1, NEUROD1 and POU2F3 as well as immune-inflammatory status, has provided a new basis for understanding the heterogeneity of immunotherapy response and for developing precision stratified treatment in ES-SCLC. To standardize the clinical translation of molecular subtyping in ES-SCLC immunotherapy, this consensus was developed by multidisciplinary experts from respiratory medicine, oncology, pathology, radiation oncology, and basic medical sciences. Based on domestic and international evidence and clinical experience, the consensus provides recommendations on key issues, including first-line immunotherapy for ES-SCLC, molecular subtyping systems and immune microenvironment characteristics, testing and implementation pathways, immunotherapy-related biomarkers, subtype-informed treatment strategies, and dynamic monitoring. This consensus emphasizes that molecular subtyping should currently be positioned as a tool for biological and clinical research stratification based on standard treatment, and should not be used as an independent basis for treatment decisions. Immunohistochemistry can serve as an important method for qualified centers to conduct subtyping exploration and translational research. The SCLC-I subtype may provide a useful reference for biomarker-based stratification and immunotherapy benefit prediction. For different subtypes, delta-like ligand 3 (DLL3)-targeted therapy, epigenetic regulation, the MYC/AURKA axis, and poly (ADP-ribose) polymerase (PARP) inhibitors can be important choices for subsequent treatment optimization. This consensus aims to standardize pathological testing and clinical application of molecular subtyping in ES-SCLC, facilitate stratified management and individualized treatment optimization based on molecular subtypes, and provide a foundation for building a precision immunotherapy system.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 7","pages":"475-490"},"PeriodicalIF":0.0,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research Progress on Circulating Tumor DNA Status and Postoperative Central Nervous System Recurrence Risk and Overall Survival in Non-small Cell Lung Cancer].","authors":"Dandan Gao, Lei Pan, Chengrui Liu, Wangping Li","doi":"10.3779/j.issn.1009-3419.2026.101.15","DOIUrl":"10.3779/j.issn.1009-3419.2026.101.15","url":null,"abstract":"<p><p>Lung cancer is one of the malignancies with the highest incidence and mortality rates worldwide, with non-small cell lung cancer (NSCLC) accounting for the vast majority. Patients with postoperative central nervous system (CNS) metastasis have a dismal prognosis, highlighting the urgent need for more precise molecular biomarkers. Although circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing can predict postoperative recurrence, its utility in detecting CNS metastasis remains debated. This review examines the association between MRD status and CNS recurrence risk, synthesizes evidence linking MRD status to overall survival (OS), and explores mechanisms underlying false-negative results of peripheral blood MRD in CNS metastasis detection alongside potential clinical strategies. Current evidence indicates that MRD positivity correlates with increased overall recurrence risk and shortened OS; some studies suggest a potential increase in CNS recurrence, yet direct evidence specifically targeting intracranial recurrence-free survival (iRFS) remains insufficient. MRD-negative patients generally have favorable prognosis; however, a subset of high-risk patients - those with epidermal growth factor receptor (EGFR) mutations, stage III disease, or adenocarcinoma - may still develop isolated CNS metastases, primarily due to the blood-brain barrier limiting ctDNA release. Adjuvant Osimertinib reduces CNS recurrence risk, though recurrence remains high within the first year after treatment discontinuation. MRD status serves as an important prognostic stratification tool after NSCLC resection, but negative peripheral blood MRD does not completely exclude CNS recurrence risk. Comprehensive assessment integrating imaging, risk factors, and cerebrospinal fluid testing is therefore warranted.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 7","pages":"525-532"},"PeriodicalIF":0.0,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Digital Drainage Systems in Postoperative Chest Tube Management\u2029after Pulmonary Resection: Current Status and Future Perspectives].","authors":"Yizhe Wang, Hongru Shen, Jing Kang, Mohan Sun, Yong Cui, Peihao Wang","doi":"10.3779/j.issn.1009-3419.2026.101.16","DOIUrl":"10.3779/j.issn.1009-3419.2026.101.16","url":null,"abstract":"<p><p>Chest drainage management is an essential component of perioperative care after pulmonary resection, aiming to evacuate intrapleural air and fluid and promote lung re-expansion. However, conventional chest drainage systems mainly rely on manual observation, making continuous and quantitative assessment of air leakage difficult and resulting in subjective decision-making regarding the timing of chest tube removal. In recent years, digital drainage systems (DDS) have been increasingly applied in clinical practice. By using integrated sensors, DDS enables continuous monitoring of pleural pressure, air flow, and fluid drainage, and provides dynamic trend curves, thereby offering objective evidence for chest tube management. DDS may improve the accuracy of drainage assessment and optimize chest tube management strategies; however, its widespread adoption remains influenced by factors such as cost, clinical experience, and healthcare system differences. This review summarizes the current application status, advantages, and challenges of DDS in postoperative chest drainage management after pulmonary resection.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 7","pages":"518-524"},"PeriodicalIF":0.0,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Advances in Systemic Therapy for Extensive-stage Small Cell Lung Cancer \u2029in the Era of Precision Treatment].","authors":"Hanrui Chen, Liwen Xu, Yixuan Cheng, Lei Zhou","doi":"10.3779/j.issn.1009-3419.2026.101.14","DOIUrl":"10.3779/j.issn.1009-3419.2026.101.14","url":null,"abstract":"<p><p>Extensive-stage small cell lung cancer (ES-SCLC) is characterized by rapid progression, a high risk of recurrence, and poor prognosis, and remains a major therapeutic challenge in lung cancer. In recent years, immune checkpoint inhibitors combined with Platinum-Etoposide chemotherapy have become the standard first-line treatment for ES-SCLC, driving a shift from conventional chemotherapy toward multimodal combination strategies and precision-guided patient stratification, while creating both new opportunities and challenges for further therapeutic improvement. Following the clinical treatment pathway, this review summarizes advances in multidisciplinary combination treatment for ES-SCLC, including chemotherapy, immunotherapy, targeted therapy, radiotherapy, and traditional Chinese medicine, with emphasis on standard regimens, maintenance therapy, clinical limitations, and emerging research directions. This review aimed to provide a reference for individualized treatment and comprehensive disease management of ES-SCLC in the era of precision medicine.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 7","pages":"500-508"},"PeriodicalIF":0.0,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[State Changes and Stability Grading of Driver Genes in Non-small Cell Lung Cancer Based on Repeated NGS Testing].","authors":"Dan Zhao, Fudong Xu, Lili Zhang, Nana Zhang, Zichen Liu, Kun Li, Chen Zhang, Lijuan Zhou, Yujie Dong, Jing Mu, Nanying Che","doi":"10.3779/j.issn.1009-3419.2026.106.18","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.18","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Next-generation sequencing (NGS)-based driver gene testing has become a routine component of molecular subtyping and precision therapy for non-small cell lung cancer (NSCLC). Dynamic genomic monitoring facilitates early detection of resistance-related molecular alterations and informs timely therapeutic adjustments. However, standardized criteria for evaluating the stability of serial NGS testing are currently lacking, and the applicability of NGS using formalin-fixed paraffin-embedded (FFPE) specimens for dynamic monitoring remains poorly defined. This study aims to establish a stability grading system for driver gene status alterations based on repeated NGS testing, and to provide evidence-based support for clinical repeat biopsy strategies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Data from 1232 patients with NSCLC who underwent two or more NGS tests on FFPE tissue specimens at Beijing Chest Hospital between June 2019 and April 2026 were collected retrospectively. Patients with an interval of ≥4 months between the initial and last tests were included to ensure the representativeness of temporal analysis, resulting in a main analysis cohort of 942 patients. The Kappa consistency test was used to evaluate the state stability of nine core driver genes [epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1, receptor tyrosine kinase (ROS1), mesenchymal‑epithelial transition factor (MET), rearranged during transfection (RET), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), erb‑b2 receptor tyrosine kinase 2 (ERBB2), and phosphatidylinositol‑4,5‑bisphosphate 3‑kinase catalytic subunit alpha (PIK3CA)] and to construct a five‑level grading system. Paired variant allele frequency (VAF) differences were compared using the Wilcoxon signed‑rank test. Independent influencing factors for mutation accumulation were identified by binary Logistic regression.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The state stability of the nine genes was classified into five levels: EGFR showed high stability (Kappa=0.838), ROS1/ALK/KRAS good stability, BRAF/PIK3CA/RET moderate stability, and ERBB2 low stability, and MET showed high instability. MET exhibited the highest rate of state change (9.3%) with a raw observed agreement of 90.7%. Its Kappa value (0.172) was influenced by the low prevalence (3.7%) compression effect and should therefore be interpreted alongside the observed agreement (90.7%) and the prevalence-adjusted and bias-adjusted Kappa (PABAK). The VAF of PIK3CA increased significantly (P=0.005). T790M positivity increased from 5.8% to 10.8%, and 30 new C797S mutations were detected at the last test (13 with T790M, 17 without). The overall rate of new driver gene variants in the main cohort was 18.0%. Binary Logistic regression showed that a lower number of initial mutated genes was the only independent predictor of new variants [odds ratio (OR)=0.399","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 7","pages":"491-499"},"PeriodicalIF":0.0,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Frontiers and Applications Progress of ctDNA in Precision Treatment\u2029of Non-small Cell Lung Cancer].","authors":"Hongmin Yu, Hua Qiao, Jie Li, Liyan Du","doi":"10.3779/j.issn.1009-3419.2026.106.22","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.22","url":null,"abstract":"<p><p>Circulating tumor DNA (ctDNA) enables minimally invasive, repeatable assessment of tumor burden and molecular evolution and is an important candidate biomarker for precision management of non-small cell lung cancer (NSCLC). This review summarizes current evidence on assay strategies, perioperative dynamics, molecular residual disease (MRD) after curative-intent treatment, relapse surveillance, and applications in unresectable stage III disease. The most consistent evidence shows that detectable ctDNA after definitive treatment is associated with a substantially increased risk of recurrence, whereas longitudinally undetectable MRD identifies lower-risk populations more reliably than a single negative result. ctDNA clearance during neoadjuvant therapy is associated with pathological response and long-term outcomes but cannot replace pathology or imaging. In oncogene-driven disease, epidermal growth factor receptor (EGFR)-mutated NSCLC has MRD evidence from samples collected in a randomized trial; a small prospective postoperative study has provided direct MRD evidence in early-stage anaplastic lymphoma kinase (ALK)- or ROS proto-oncogene 1, receptor tyrosine kinase (ROS1)-fusion-positive disease, although the evidence base remains limited; Kirsten rat sarcoma viral oncogene homolog (KRAS), GTPase specific postoperative MRD studies remain insufficient. When pathology, imaging, and ctDNA are discordant, assay validity should first be confirmed and lesion-directed imaging or tissue confirmation pursued according to the suspected relapse pattern; ctDNA alone should not trigger deviation from standard therapy. ctDNA has substantial clinical validity, but routine treatment decisions still require standardized analytical performance, cross-platform reproducibility, and prospective evidence of clinical utility.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 7","pages":"509-517"},"PeriodicalIF":0.0,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Etiology, Evaluation and Comprehensive Management of Hoarseness \u2029after Lung Cancer Surgery].","authors":"Pengfei Men, Jialin Liang, Feng Zhang, Xiaolong Wang","doi":"10.3779/j.issn.1009-3419.2026.106.21","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.21","url":null,"abstract":"<p><p>Hoarseness after lung cancer surgery is a common but often underestimated perioperative functional complication. Beyond impairing voice quality, it may involve swallowing dysfunction and compromised airway protection, thereby increasing the risk of aspiration, pulmonary infection, and delayed recovery. Iatrogenic recurrent laryngeal nerve injury is the major cause, closely associated with mediastinal lymph node dissection, with the left lower paratracheal lymph node station as typical high-risk anatomical areas. Nerve injury results from both direct mechanical trauma and indirect mechanisms such as traction and thermal spread. In addition, intubation-related laryngeal trauma can also present as postoperative hoarseness and should be differentiated from neurogenic causes. This review summarizes the etiology and risk factors, outlines postoperative evaluation and preventive strategies, and discusses the role of meticulous dissection, minimized thermal injury, and appropriate intraoperative neuromonitoring. Future prospective studies are needed to standardize outcomes and clarify the optimal timing and target populations for interventions, ultimately improving comprehensive perioperative management and patients' quality of life.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 7","pages":"533-539"},"PeriodicalIF":0.0,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Tumor Cell and Brain Microenvironment Interactions in Non-small Cell Lung Cancer \u2029Brain Metastasis: Mechanisms and Emerging Insights].","authors":"Heqi Yang, Qinghua Zhou","doi":"10.3779/j.issn.1009-3419.2026.102.21","DOIUrl":"10.3779/j.issn.1009-3419.2026.102.21","url":null,"abstract":"<p><p>Brain metastasis in non-small cell lung cancer (NSCLC) is shaped by continuous interactions between tumor cells and the brain-specific microenvironment. Vascular, glial and immune components contribute to intracranial colonization, immune escape and therapeutic resistance, while single-cell and spatial omics reveal heterogeneity in cellular states, communication networks and spatial niches. This review summarizes NSCLC brain metastasis and intracranial colonization, the brain metastatic microenvironment and tumor-microenvironment interactions, and discusses the heterogeneity revealed by single-cell and spatial omics and its potential relevance to therapeutic response and patient stratification.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 7","pages":"548-556"},"PeriodicalIF":0.0,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Perioperative Safety Analysis of Preoperative Targeted Therapy in Patients \u2029with ALK-positive Non-small Cell Lung Cancer].","authors":"Mengying Fan, Cunwei Qin, Yifan Fang, Hao Fu, Liang Dai, Yongbo Yang, Zhen Liang, Hongchao Xiong, Wanpu Yan, Keneng Chen","doi":"10.3779/j.issn.1009-3419.2026.106.19","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.19","url":null,"abstract":"<p><strong>Background: </strong>Perioperative management of locally advanced non-small cell lung cancer (NSCLC) remains a significant clinical challenge. Although anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) have established a definitive role in the adjuvant setting for ALK-positive NSCLC, clinical evidence supporting their preoperative application remains scarce. Recent exploratory trials, such as the ALNEO study, indicated that preoperative ALK-TKIs therapy can achieve favorable major pathological response (MPR) rates; however, documented data regarding its perioperative safety remain limited. This study aims to evaluate the perioperative safety and feasibility of preoperative ALK-TKIs therapy through a retrospective, single-center analysis.</p><p><strong>Methods: </strong>A retrospective review was conducted using the data of ALK-positive NSCLC patients recorded in the prospective database of Department I of Thoracic Surgery at Peking University Cancer Hospital from 2021 to 2024, who underwent surgical resection following preoperative ALK-TKIs therapy. Short-term efficacy, surgical outcomes, perioperative complications, and long-term survival data were systematically evaluated.</p><p><strong>Results: </strong>Eleven patients were included, predominantly consisting of female non-smokers (9/11), and the pathological type for all patients was adenocarcinoma. Baseline clinical staging included stage IIIA (n=7), stage IIIB (n=3), and stage IV with oligometastasis (n=1). All patients received preoperative ALK-TKIs, with 4 receiving concurrent chemotherapy. The objective response rate (ORR) was 81.8%. All patients successfully underwent surgery via video- or robotic-assisted thoracoscopic surgery. The mean operative time was (122.0±62.3) min and the median intraoperative blood loss was 74.0 mL (range: 5.0-300.0 mL). The MPR and pathological complete response (pCR) rates were 45.5% (5/11) and 27.3% (3/11), respectively. All patients received postoperative adjuvant therapy, primarily targeted drugs. At a median follow-up of 30 months, no deaths occurred in the entire cohort; however, three patients experienced disease recurrence (one with intestinal and liver metastases, and two with brain metastases).</p><p><strong>Conclusions: </strong>Preoperative ALK-TKIs therapy demonstrates favorable safety and feasibility in this small-sample cohort of ALK-positive NSCLC patients.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 6","pages":"420-427"},"PeriodicalIF":0.0,"publicationDate":"2026-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13482754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}